7 Chinese vaccines enter phase-3 clinical trials
Print Edition
A TOTAL of seven Chinese-made COVID-19 vaccines have entered phase-three clinical trials, according to an official with the Ministry of Science and Technology.
China now has 16 self-developed COVID-19 vaccines undergoing clinical trials, said Wu Yuanbin, director-general of science and technology for social development with the ministry, at a recent conference on hematology.
According to the Chinese Center for Disease Control and Prevention, more than 24 million doses of COVID-19 vaccines had been administered in China by yesterday.
The two vaccines currently in use in China, the China National Biotec Group COVID-19 vaccine and the CoronaVac vaccine developed by China’s Sinovac Biotech Ltd, are both inactivated vaccines that are relatively safe, renowned respiratory-disease expert Zhong Nanshan said.
“The rate of the vaccines’ mild adverse reactions, which include fever, soar arms and other symptoms, is six per 100,000 people,” Zhong said at the launch ceremony of an event held in south China’s Guangdong Province to promote the use of technology in COVID-19 prevention and control.
The rate of severe adverse vaccine reactions is one in a million, only one third of that of flu vaccines, he said.
Xu Wenbo, head of the National Institute for Viral Disease Control and Prevention under the China CDC, said the incidence of severe abnormal reactions caused by the COVID-19 vaccines is no higher than that of the influenza vaccines.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
